Innate Pharma S.A. Sponsored ADR
Innate Pharma S.A. Sponsored ADR is a biotechnology company focused on developing immunotherapies for cancer patients. The company uses antibody engineering and natural killer cell-based approaches to build treatments aimed at harnessing the innate immune system, with a pipeline that includes programs for hematologic cancers and solid tumors. Its current work spans clinical-stage drug development, research collaborations, and licensing arrangements with major pharmaceutical partners, reflecting a business model centered on advancing proprietary candidates through development while leveraging partnerships to broaden its therapeutic reach. Innate Pharma operates primarily in the oncology and immunotherapy segments of the healthcare market, serving as a specialized developer of next-generation antibody-based medicines. Headquartered in Marseille, France, it maintains an international presence through research and collaboration activities that support its role in modern cancer drug development.
$1.43
-$0.05 (-3.38%)
EOD Oct 16, 2026
The business is unprofitable at the operating level (-1916.94% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 77.9% YoY. Margins deteriorated 1508.3pp alongside, both lines moving the wrong way.
ROIC dropped from -61.91% to -135.27%, capital efficiency is deteriorating. Negative free cash flow of -€35M. The business is consuming cash, not generating it.
Price History
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
€3M
▼ -77.9% YoY
Net Income (TTM)
-€49M
▲ +0.6% YoY
Op. Margin
-1916.94%
▼ -1508.3pp YoY
ROIC
-135.27%
▼ -73.4pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-€35M
▼ -379.1% YoY
Op. Cash Flow (TTM)
-€33M
▼ -372.1% YoY
Net Debt
-€12M
Net Cash Position
Cash & Equiv.
€34M
3Y CAGR: -61.7%
Continue Research
Is Innate Pharma S.A. Sponsored ADR (IPHA) overvalued?
Innate Pharma S.A. Sponsored ADR (IPHA)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Innate Pharma S.A. Sponsored ADR scores 10/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from company filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.
Frequently asked
Is Innate Pharma S.A. Sponsored ADR a high-quality business?+
Innate Pharma S.A. Sponsored ADR scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -1,916.9% operating margin and a -135.3% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from company filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Is Innate Pharma S.A. Sponsored ADR a good stock to buy right now?+
That depends on valuation and quality together, not either alone. you should weigh IPHA's valuation and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from company filings, not investment advice.
Related stocks: Biotechnology
Spot a number that looks wrong?
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.